Dermacell AWM is a technologically advanced human acellular dermal matrix that is decellularized using Matracell®, a proprietary, patented, and validated processing technology. Matracell removes a minimum of 97% of donor DNA1, allowing for rapid cellular infiltration and re-vascularization. Dermacell AWM is terminally sterilized, ready to use without refrigeration or re-hydration.
Biohospitable: All cells ≥ 97% donor DNA removed to potentially minimize any adverse patient response.
Intact Acellular Framework: Retains native growth factors, collagen and elastin.
Room Temperature Storage: Ready to use out of the package (15°C- 30°C).
Proven: Conducted the largest randomized controlled trial (RCT) to date using hADM in chronic wounds.2
Clinical Applications
- Chronic wounds such as diabetic foot ulcers (DFUs), venous stasis ulcers (VSUs), arterial ulcers and pressure ulcers, as well as dehisced surgical wounds and traumatic burns
- Dermacell AWM can be used over exposed tendon, bone, joint capsule, and muscle
1. Moore MA, Samsell B, Wallis G, Triplett S, Chen S, Linthurst Jones A, Qin X. Decellularization of human dermis using non-denaturing anionic detergent and endonuclease: a review. Cell Tissue Bank. 2015;16(2):249-259.
2. Cazzell, S., Vayser, D., Pham H., et al. A randomized clinical trial of a human acellular dermal matrix demonstrated superior healing rates for chronic diabetic foot ulcers over conventional care and an active acellular dermal matrix comparator. Wound Repair and Regeneration. 2017. 25(3):483-497.